Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2020 01:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update

NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
February 04, 2020 04:45 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference

NEW YORK, Feb. 04, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative diseases,...
January 29, 2020 04:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Receives Notice of Intention to Grant Additional EU patent for NurOwn®

NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that...
January 21, 2020 09:52 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutic’s COO and CMO, Dr. Ralph Kern, to Present at the 10th Annual California ALS Research Summit

NEW YORK and LOS ANGELES, Jan. 21, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases,...
January 07, 2020 01:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week

NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that...
December 19, 2019 05:00 ET | Source: BrainStorm Cell Therapeutics Inc.

NurOwn® Data Safety Monitoring Board Recommends MS Phase 2 Clinical Trial Continue

NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that the...
December 18, 2019 05:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Issues 2019 Letter to Shareholders

NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapeutics for neurodegenerative diseases, today issued a Letter to...
December 11, 2019 05:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Selected as Buzz of BIO 2020 Winner

NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
November 26, 2019 08:05 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND

NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
November 25, 2019 06:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Announces the Mount Sinai Medical Center as a Progressive MS Phase 2 Clinical Trial Site

NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...